Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab plus azacitidine versus physician's choice therapy in previously untreated TP53-mutant acute myeloid leukemia
jRCT2071220076Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of magrolimab, azacitidine, venetoclax, cytarabine, daunorubicin and 1 more in acute myeloid leukemia (AML) (3 arms), sponsored by Gilead Sciences. Primary endpoint: Overall Survival in participants appropriate for non-intensive therapy. Started Dec 2022; status: completed.
02
Drugs
magrolimabazacitidinevenetoclaxcytarabinedaunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2071220076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220076.